期刊
NPJ BREAST CANCER
卷 7, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41523-021-00334-5
关键词
-
类别
资金
- NIH [P30CA008748]
- Breast Cancer Research Foundation
- Geoffrey Beene Cancer Research Center
The research identified specific genetic and immune features in some triple-negative breast cancer patients who experienced rapid fatal recurrence after neoadjuvant chemotherapy, suggesting potential biomarkers for resistance to treatment and disease progression.
To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E. Six patients experienced a rapid fatal recurrence (RR) and other 6 had later non-fatal recurrences (LR). Before NAT, RR had low expression of 6 MHC class I and 13 MHC class II genes but were enriched in upregulated genes involved in the cell cycle-related pathways. Their TIL number before NAT in RR was very low (<5%) and did not increase after treatment. In post-NAT residual tumors, RR cases showed high expression of SOX2 and CXCR4. Our results indicate that high expression of cell cycle genes, combined with cold immunological phenotype, may predict strong NBC resistance to NAT and rapid progression after it. This biomarker combination is worth validation in larger studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据